Vertex Pharmaceuticals recently reported a significant revenue jump to $2,965 million in Q2 2025. Despite this success, the ...

Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company ...

Vertex Pharmaceuticals shares fell 14% in post-market trading Monday after the company said it will not advance its ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

The outcome of the study was just one setback reported by Vertex as it updated investors on its second-quarter results, ...